Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 1997

View Archived Issues

New immunosuppressants in the pipeline at Merck & Co.

IL-5 receptor ligands reported by Glaxo Wellcome

New antifungals disclosed by Schering-Plough

New photodynamic agents reported by Novartis

Improved method for vWF purification developed by Bayer

HMR discloses new anti-HIV agents

UPSA claims new COX-2 inhibitors for inflammation, pain and other disorders

New orally active antihypertensive compounds prepared at Rotta

Cytogen updates stockholders

Potent and selective AMPA antagonist from Roche

FR-208419: a new dual CCK-A and CCK-B/gastrin receptor antagonist

Banyu searches for potent, orally bioavailable FXa inhibitors

Favorable phase III trial results reported for HER2 monoclonal antibody

Cambridge Antibody Technology: FY 1997 highlights

FDA deems Provigil approvable

Raxar --new once-daily fluoroquinolone-- now available in U.S.

Commencement of phase II trials of LiquiVent for adult ARDS

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...